Loading…
Werewolf Therapeutics, Inc. is projected to decline to $0.3948 by 2027, a -2% move from its current price of $0.403. HOWL is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.3826 | $0.4029 | $0.4243 | -0.02% |
| Jul 14 | $0.3744 | $0.4028 | $0.4334 | -0.05% |
| Jul 15 | $0.3682 | $0.4027 | $0.4405 | -0.07% |
| Jul 16 | $0.3631 | $0.4026 | $0.4465 | -0.10% |
| Jul 17 | $0.3586 | $0.4025 | $0.4519 | -0.12% |
| Jul 18 | $0.3545 | $0.4024 | $0.4568 | -0.14% |
| Jul 19 | $0.3509 | $0.4023 | $0.4613 | -0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3509 | $0.4023 | $0.4613 | -0.17% |
| Week 2 | $0.331 | $0.4017 | $0.4874 | -0.33% |
| Week 3 | $0.3164 | $0.401 | $0.5082 | -0.50% |
| Week 4 | $0.3045 | $0.4003 | $0.5263 | -0.66% |
| Week 5 | $0.2943 | $0.3997 | $0.5427 | -0.83% |
| Week 6 | $0.2854 | $0.399 | $0.5579 | -1.00% |
| Week 7 | $0.2773 | $0.3983 | $0.5721 | -1.16% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Werewolf Therapeutics, Inc. is a biopharmaceutical company that engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer.
Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
HOWL is the stock ticker for Werewolf Therapeutics, Inc. and the current price is $0.3785. Its market capitalization is $18.39M and it ranks 4951. The price outlook, as captured in the forecast, shows a path of gradual gains over time, with notable anchors including 2032 max $0.9359 and 2040 max $1.42, culminating in a 2050 max of $2.48.
The forecast also shows future average prices rising from about $0.3234 in 2030 to $1.08 by 2050, with a 2050 average of $1.08 and a 2050 max of $2.48. Overall, the horizon presents a mix of neutral and bullish years, with meaningful upside in the long run but near-term variability.
A major floor 41.9% below — a decisive break under it would weaken the trend.
The nearest floor, 23.6% below — buyers have tended to step in here.
The nearest ceiling, 15.6% above — a clean break opens room to run.
A major ceiling 158.1% above — clearing it would confirm fresh momentum.
Key HOWL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HOWL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.3612 | Buy | $0.3722 | Buy |
| MA 10 | $0.349 | Buy | $0.362 | Buy |
| MA 20 | $0.3575 | Buy | $0.3721 | Buy |
| MA 50 | $0.4573 | Sell | $0.4626 | Sell |
| MA 100 | $0.6289 | Sell | $0.5885 | Sell |
| MA 200 | $0.8599 | Sell | $0.7943 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.31 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 151.29 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 11.33 | Buy |
| Bollinger %B (20,2) | 0.96 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -1.38 | Sell |
| Awesome (5,34) | -0.03 | Sell |
| Ultimate (7,14,28) | 61.97 | Neutral |
| Momentum (10) | 0.07 | Buy |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 0.38 | Buy |
| ADX (14) | 26.11 | Buy |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 50, and the 50‑day simple moving average is $0.4641 while the 200‑day simple moving average is $0.8671.
Support is at $0.308 and resistance at $0.49. The 30‑day range spans $0.2694 to $0.5318, indicating a relatively tight trading band over the period. Annualized volatility is 100%, underscoring substantial swings in this price range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.308 | $0.403 | $0.5135 | 0% | Neutral | |
| $0.2882 | $0.3948 | $0.5842 | -2% | Neutral | |
| $0.2358 | $0.3424 | $0.5391 | -15% | Bearish | |
| $0.2173 | $0.3317 | $0.5477 | -18% | Bearish | |
| $0.2228 | $0.3559 | $0.6113 | -12% | Neutral | |
| $0.2672 | $0.4451 | $0.7908 | +10% | Neutral | |
| $0.3243 | $0.5625 | $1.03 | +40% | Bullish | |
| $0.2775 | $0.5002 | $0.9407 | +24% | Bullish | |
| $0.2416 | $0.4521 | $0.8713 | +12% | Neutral | |
| $0.2673 | $0.519 | $1.02 | +29% | Bullish | |
| $0.3278 | $0.7284 | $1.58 | +81% | Bullish | |
| $0.5542 | $1.23 | $2.83 | +206% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.308 | $0.403 | $0.4888 | +0.00% |
| August 2026 | $0.3383 | $0.4091 | $0.5147 | +1.50% |
| September 2026 | $0.3217 | $0.3943 | $0.5063 | -3.60% |
| October 2026 | $0.2948 | $0.3656 | $0.4775 | -7.28% |
| November 2026 | $0.2944 | $0.3688 | $0.4884 | +0.86% |
| December 2026 | $0.3027 | $0.3829 | $0.5135 | +3.81% |
Click any year to see its month-by-month HOWL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The HOWL price prediction for 2026 points to an average of $0.403 (low $0.308, high $0.5135) — a potential gain of 0% on today's $0.403. A consolidation phase looks the most probable path here.
In 2027, HOWL is projected to trade between $0.2882 and $0.5842, averaging $0.3948 — a potential decline of -2% from today's $0.403. That is -2% versus the projected 2026 average. Price action looks broadly range-bound.
Werewolf Therapeutics, Inc.'s 2028 outlook centres on $0.3424, within a $0.2358 to $0.5391 range. That is -13% versus the projected 2027 average. That marks a -15% change versus current levels. Expect choppier, lower action through this leg of the cycle.
By 2029, HOWL could reach as high as $0.5477, with a base case around $0.3317 and support toward $0.2173 — roughly -18% from $0.403. A cyclical pullback looks likely — prices rarely move in a straight line.
Expect HOWL to range from $0.2228 to $0.6113 through 2030. The $0.3559 average target implies a -12% move from current prices. That is up +7% on the projected 2029 average. A consolidation phase looks the most probable path here.
The HOWL price prediction for 2031 points to an average of $0.4451 (low $0.2672, high $0.7908) — a potential gain of +10% on today's $0.403. Price action looks broadly range-bound.
In 2032, HOWL is projected to trade between $0.3243 and $1.03, averaging $0.5625 — a potential gain of +40% from today's $0.403. That is up +26% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Werewolf Therapeutics, Inc.'s 2033 outlook centres on $0.5002, within a $0.2775 to $0.9407 range. That is -11% versus the projected 2032 average. That marks a +24% change versus current levels. Momentum favours further upside here.
By 2034, HOWL could reach as high as $0.8713, with a base case around $0.4521 and support toward $0.2416 — roughly +12% from $0.403. A consolidation phase looks the most probable path here.
Expect HOWL to range from $0.2673 to $1.02 through 2035. The $0.519 average target implies a +29% move from current prices. That is up +15% on the projected 2034 average. Momentum favours further upside here.
The HOWL price prediction for 2040 points to an average of $0.7284 (low $0.3278, high $1.58) — a potential gain of +81% on today's $0.403. Buyers look set to stay in control over this stretch.
In 2050, HOWL is projected to trade between $0.5542 and $2.83, averaging $1.23 — a potential gain of +206% from today's $0.403. That is up +69% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in HOWL today (≈ 2,481.389578 HOWL) could be worth
$3,055.93
+$2,055.93 (+206%) by 2050 · US Dollar
Based on the average projected HOWL price of $1.23 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HOWLwould be worth at today's price.
$1,000 invested in HOWL on Jul 10, 2025 (≈ 925.925889 HOWL) would be worth
$373.15
-$626.85 (-62.7%) today · 0.37× · US Dollar
Based on a HOWL entry price of $1.08 vs. today's $0.403.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.34 | $1,185.29 | +18.5% |
| 1 month ago | $0.365 | $1,104.11 | +10.4% |
| 3 months ago | $0.849 | $474.68 | -52.5% |
| 6 months ago | $0.575 | $700.87 | -29.9% |
| 1 year ago | $1.08 | $373.15 | -62.7% |
| All time (5.0y) ago | $15.42 | $26.13 | -97.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HOWL forecast.
Our base-case forecast reaches $0.81 around 2050.
Implied market cap at $0.81: $39.36M
The multi-year forecast shows a varied path across the horizon. In 2026 the avg is $0.3785 with a neutral sentiment and 0% ROI. The path includes negative years such as 2027 at -2.5%, 2028 at -15.3%, and 2029 at -19.1%, before turning more positive in 2031 and onward.
By 2030 the avg is $0.3234 and the ROI is -14.6%; by 2031 the avg rises to $0.4042 with a 6.8% ROI, and 2032 shows a strong inflection to $0.5116 with a 35.2% ROI.
2033 delivers an avg of $0.4557 with a 20.4% ROI, and 2034 shows $0.4147 with a 9.6% ROI. In 2035 the avg reaches $0.4715 and the ROI is 24.6%. The horizon then advances to 2040 with an avg of $0.6577 and a 73.8% ROI, and 2050 with an avg of $1.08 and a 185.1% ROI, reaching a max of $2.48.
Bulls dominate the late horizon, while earlier years carry notable risks.
These figures are estimates and not guarantees. The forecast includes a mix of neutral to bullish years, with substantial upside possible in the long run and meaningful downside risk in certain years.
Tap a question to reveal the answer.
2030 avg $0.3234 with a range from $0.2027 to $0.5551 and an ROI of -14.6%; sentiment NEUTRAL.
The forecast includes years with negative ROI (2027 -2.5%, 2028 -15.3%, 2029 -19.1%, 2030 -14.6%) and years with strong upside (2040 73.8%, 2050 185.1%). Overall, it is a high‑risk scenario with substantial uncertainty; these are estimates, not guarantees.
Yes—the 2050 max forecast is $2.48, indicating the potential to exceed $2.
Current price is $0.3785 and market cap is $18.39M.
2032 avg $0.5116; min $0.2953; max $0.9359; ROI 35.2%; sentiment BULLISH.
Werewolf Therapeutics, Inc. Community Discussion
0Share your Werewolf Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.